Released Nov 9, 2021, before the open
10-Q filed Nov 9, 2021, 40 days after period end · 0001628280-21-022556
Q3 2021 · 10-Q
Revenue$41.00K$41.00K −77.1% vs Q3 2020−85.3% vs Q2 2021
Net Income-$26.08M-$26.08M N/M vs Q3 2020N/M vs Q2 2021
EPS Diluted-$0.71-$0.71 N/M vs Q3 2020N/M vs Q2 2021
Operating Income-$26,261,000N/M
Operating Cash Flowderived-$20,502,000N/M
Free Cash Flowderived-$20,732,000N/M
Margins · derived
Operating margin-64051.2%−53722.2 pt vs Q3 2020
Net margin-63609.8%−53348.9 pt vs Q3 2020
What the release said
The release
Same quarter
| Metric | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|
| Revenue | $41.00K | $179.00K | — |
| Net Income | -$26.08M | -$18.37M | -$13.09M |
| EPS Diluted | -$0.71 | -$3.12 | -$3.05 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR